stockrow
Friday 6 November 2026
Export USNA’s income statement to Excel — free account
USANA Health Sciences, Inc.
USNA Consumer Defensive Packaged Foods
USANA Health Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $925.3 million, up 8.28% from fiscal 2024.
- Revenue
- −3.64%
- EPS
- −3.47%
- Free cash flow
- +180.6%
Quarter to September 2026, against a year earlier
13.58
0.28
−2.02%
Follow USNA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
35.69 | 37.17 | 0.00 | 0.00 |
P/S ratio |
0.39 | 0.35 | 0.43 | 0.30 | |
P/FCF ratio |
29.27 | 46.49 | 19.83 | 13.45 | |
P/Operating CF |
(107.33) | 32.94 | 16.93 | 11.48 | |
P/B ratio |
0.68 | 0.59 | 0.75 | 0.51 | |
Price to Tangible BV |
1.39 | 1.16 | 1.35 | 0.90 | |
EV/Sales |
0.29 | 0.24 | 0.32 | 0.17 | |
EV/EBITDA |
3.52 | 3.00 | 4.37 | 2.31 | |
EV/Operating CF |
12.15 | 13.51 | 10.54 | 5.58 | |
EV/FCF |
21.84 | 32.49 | 14.68 | 7.78 | |
Quick Ratio |
1.27 | 1.47 | 1.63 | 1.64 | |
Current Ratio |
2.24 | 2.51 | 2.66 | 2.59 | |
Net Debt/EBITDA |
(11.23) | (6.88) | (9.21) | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.24 | 1.25 | 1.27 | 1.26 | |
Operating CF/Net income |
1.91 | 1.30 | (1.09) | 0.00 | |
Capex/Depreciation |
0.11 | (0.27) | (0.08) | — | |
Interest Coverage |
31.05 | 57.81 | — | (38.11) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
73.39% | 70.70% | 74.26% | 77.04% | |
Intangible Assets out of Total Assets |
0.36 | 0.36 | 0.33 | 0.32 | |
Share Based Compensation of Revenue |
1.66% | 1.38% | 1.52% | 0.00% | |
Graham Net Nets |
0.22 | 0.31 | 0.26 | 0.41 | |
Graham Number |
18.87 | 17.68 | 0.00 | 0.00 | |
Earnings Yield |
2.80% | 2.69% | (5.67%) | (8.45%) | |
Free Cash Flow Yield |
3.42% | 2.15% | 5.04% | 7.44% | |
Revenue per Share |
12.20 | 13.60 | 12.08 | 11.13 | |
Operating CF per Share |
(0.18) | 0.53 | 1.26 | 0.00 | |
Capex per Share |
0.06 | (0.14) | (0.17) | 0.00 | |
Free Cash Flow per Share |
(0.12) | 0.39 | 1.09 | 0.00 | |
Cash per Share |
8.54 | 8.85 | 9.12 | 9.67 | |
Shareholders Equity per Share |
28.76 | 29.54 | 28.47 | 28.48 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
28.76 | 29.54 | 28.47 | 28.48 | |
Free Cash Flow |
(2.28) | 7.16 | 20.18 | — | |
Working Capital |
159.84 | 176.99 | 175.39 | 177.99 | |
Capital Expenditures |
1.11 | (2.60) | (3.14) | — | |
Net Current Asset Value |
78.59 | 98.82 | 104.16 | 108.53 | |
EV/EBIT |
7.25 | 6.30 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
9.72 | 9.02 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.52 | 8.54 | 5.25 | 6.12 | |
Average Payables |
14.62 | 15.10 | 16.67 | 16.94 | |
Average Inventory |
86.17 | 84.96 | 84.81 | 87.43 | |
Average Assets |
745.55 | 742.78 | 718.87 | 717.53 | |
Average Common Equity |
532.61 | 536.66 | 528.68 | — |
Columns are period end dates · fundamentals updated 5 Nov 2026